Daily Archives: March 26, 2021

Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research – BioSpace

Posted: March 26, 2021 at 6:26 pm

The two companies will launch in Korea Ocean Genomics advanced AI-based transcriptome analysis and biomarker platform (txome.ai) as both a cloud-based and on-premises solution. Geninus will leverage the txome.ai platform to expand its CancerSCAN clinical diagnostics platform for its hospital customers, and for biomarker discovery services with academic and biotechnology clients. Ocean Genomics and Geninus will also partner on the co-development of a series of RNA-informed multidimensional biomarkers for research and clinical use.

We are excited to embark on this partnership with Geninus said Carl Kingsford, co-founder and CEO, Ocean Genomics. Ocean Genomics expertise in AI and computational method development, together with Geninus translational experts and access to data is a powerful combination. Working together, we can advance the field and enhance the uses of RNA biomarkers in clinical and research applications and provide essential insights for clinicians who care for cancer patients.

Dr. Woong Yang Park, CEO, Geninus, said, Genome analysis for precision cancer medicine is becoming an essential process in hospitals. Gene expression analysis on tumor tissue RNA can deliver critical information for targeted therapy and immunotherapy. We expect to advance precision medicine by incorporating Ocean Genomics txome.ai into Geninus clinical diagnostics platform, CancerSCAN. We look forward to working with Ocean Genomics in co-developing biomarkers and expanding services to our academic and biotechnology customers.

About Ocean Genomics, Inc.

Ocean Genomics mission is to enable drug development and personalized medicine by combining AI with advanced gene-expression analysis to determine rich gene expression signatures and develop RNA-informed multidimensional biomarkers. DNA is a predictor of what might happen in the future, while RNA reveals whats happening now, making it an essential component in drug development, screening and monitoring, diagnosis and treatment selection. Analyzing RNA requires far more advanced software and computational methods than analyzing DNA.

Ocean Genomics provides the required specialized expertise in AI and transcriptomic analysis and advanced computational software solutions required to power discovery and development programs with life sciences companies and academic researchers. Ocean Genomics provides a self-service, fully configured, cloud-based platform, txome.ai, which provides advanced transcriptome analysis and biomarker generation.

For more information, please visit oceangenomics.com and connect with us on Twitter, and LinkedIn.

About Geninus Inc.

Geninus provides clinical genome analysis solutions for precision medicine clinics. CancerSCAN, a cancer genome diagnostics platform, is used to inform personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. CancerSCAN includes an information management system, a bioinformatics pipeline, variant annotation, clinical reports, and datacenter. OncoSTATION, a user interface for CancerSCAN, can be installed within hospital information systems. In addition, Geninus operates a single cell genome analysis platform called Celinus for biomarker discovery. Through collaborations with clinicians and pharmaceutical companies, Celinus can unearth new druggable targets or diagnostic markers in tumor microenvironment cells.

For more information, please visit kr-geninus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005559/en/

See more here:
Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research - BioSpace

Posted in Gene Medicine | Comments Off on Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research – BioSpace

BNTC Stock Price Increased 190.28%: Why It Happened – Pulse 2.0

Posted: at 6:26 pm

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) a development-stage biotechnology company that focuses on the development of novel genetic medicines increased by 190.28% today as it went from a previous close of $3.19 to $9.26. The company shares were trading at over 80% pre-market today as well. Investors were responding to a Schedule 13G filing that showed Morgan Stanley now has 249,174 shares in the company, representing a 5.2% stake.

Last month, Benitec Biopharma had announced the successful results of the interim analysis of the BB-301 Pilot Dosing Study. And the proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference (RNAi) with classical AAV-based gene therapy.

And through the use of the ddRNAi platform Benitecs goal is to create genetic medicines that (following a single administration) will enable target tissues to perpetually produce siRNA molecules which facilitate the sustained silencing of disease-causing genes. The ddRNAi platform also allows for concomitant delivery of wild-type replacement genes and these distinct genetic elements work in concert to silence the expression of disease-causing mutant genes and to simultaneously replace the mutant genes with normal (wild type) genes to restore the natural underlying physiology of the diseased tissues.

BB-301, the most advanced genetic medicine currently under development by Benitec, employs the proprietary platform which allows for a Silence and Replace approach to the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). And BB-301 is a genetic medicine employing the Silence and Replace approach for the treatment of OPMD.

OPMD is known as a chronic life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. OPMD is caused by a mutation in the gene encoding poly(A) binding protein nuclear 1 (PABPN1). And patients with OPMD lose the ability to swallow liquids and solids, and the natural history of the disorder is characterized by chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia.

There are no therapeutic agents approved for the treatment of OPMD. Unfortunately, there is not any surgical interventions capable of altering the long-term natural history of OPMD are available. And BB-301 received Orphan Drug Designation in the United States and the European Union which provides commercial exclusivity (independent of intellectual property protection) and opportunities for efficient pathways for regulatory review and approval. While OPMD is a rare (Orphan) disorder, the commercial opportunity for a safe and efficacious therapeutic agent in this indication exceeds $1 billion over the course of the commercial life of the product.

Benitec had scheduled a Scientific Advice Meeting in France in May 2021 to review the interim data and the Phase 1 clinical trial design. And the company continues to plan for the initiation of the first-in-human clinical study of BB-301 in OPMD patients in 2022. The interim data validated the promise of the Silence and Replace approach to disease management and Benitec plans to provide additional pipeline updates in the second half of 2021.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Link:
BNTC Stock Price Increased 190.28%: Why It Happened - Pulse 2.0

Posted in Gene Medicine | Comments Off on BNTC Stock Price Increased 190.28%: Why It Happened – Pulse 2.0

BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened – Pulse 2.0

Posted: at 6:26 pm

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) a development-stage biotechnology company that focuses on the development of novel genetic medicines increased by over 80% pre-market. Investors are responding to a Schedule 13G filing showing that Morgan Stanley now has 249,174 shares in the company.

Last month, Benitec Biopharma had announced the successful results of the interim analysis of the BB-301 Pilot Dosing Study. The proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference (RNAi) with classical AAV-based gene therapy.

And through the use of the ddRNAi platform Benitecs goal is to create genetic medicines that, following a single administration, will enable target tissues to perpetually produce siRNA molecules which facilitate the sustained silencing of disease-causing genes. The ddRNAi platform also allows for concomitant delivery of wild-type replacement genes, and these distinct genetic elements work in concert to silence the expression of disease-causing mutant genes and to simultaneously replace the mutant genes with normal (wild type) genes to restore the natural underlying physiology of the diseased tissues.

And BB-301, the most advanced genetic medicine currently under development by Benitec, employs the proprietary platform which allows for a Silence and Replace approach to the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is a genetic medicine employing the Silence and Replace approach for the treatment of OPMD.

OPMD is known as a chronic life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. And OPMD is caused by a mutation in the gene encoding poly(A) binding protein nuclear 1 (PABPN1). Patients with OPMD lose the ability to swallow liquids and solids, and the natural history of the disorder is characterized by chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia.

There are no therapeutic agents approved for the treatment of OPMD. And there is not any surgical interventions capable of altering the long-term natural history of OPMD are available. BB-301 received Orphan Drug Designation in the United States and the European Union which provides commercial exclusivity (independent of intellectual property protection) and opportunities for efficient pathways for regulatory review and approval. While OPMD is a rare (Orphan) disorder, the commercial opportunity for a safe and efficacious therapeutic agent in this indication exceeds $1 billion over the course of the commercial life of the product.

Benitec had scheduled a Scientific Advice Meeting in France in May 2021 to review the interim data and the Phase 1 clinical trial design. And the company continues to plan for the initiation of the first-in-human clinical study of BB-301 in OPMD patients in 2022. The interim data validated the promise of the Silence and Replace approach to disease management and Benitec plans to provide additional pipeline updates in the second half of 2021.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Read the original here:
BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened - Pulse 2.0

Posted in Gene Medicine | Comments Off on BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened – Pulse 2.0

Why Do We Age, and Can Anything Be Done to Stop or Slow it? – Healthline

Posted: at 6:26 pm

Aging refers to the physiological changes we experience during our lifespan. Its also an inevitable part of life.

After all, our cells arent made to last forever. The structures and functions in our cells decline over time.

But why does this happen? For decades, scientists have been studying the subject. There are currently more than 300 theories on why we age, and experts are learning more every day.

Lets explore why humans age, and how you can slow down the effects.

Aging can be categorized into two types:

Cellular aging is due to intrinsic factors. Its related to the biological aging of cells.

Cells are the basic building blocks of the body. Your cells are programmed to divide, multiply, and perform basic biological functions.

But the more cells divide, the older they get. In turn, cells eventually lose their ability to function properly.

Cellular damage also increases as cells get older. This makes the cell less healthy, causing biological processes to fail. Cellular damage accumulates over time, too.

Damage-related and environmental aging is related to extrinsic factors. It refers to how our surroundings and lifestyle affect how we age.

This includes factors like:

Over time, these factors can damage our cells and contribute to aging.

Everyone experiences both types of aging. However, each form of aging varies from person to person, which explains why we age in different ways.

Its generally accepted that aging is caused by multiple processes, rather than one reason. Its also likely that these processes interact and overlap with each other.

Here are some of the most prominent theories:

Programmed aging theories posit that were programmed, or designed, to age. It maintains that cells have a predetermined lifespan thats naturally encoded into the body.

Programmed theories are also called active or adaptive aging theories. These theories include:

Programmed theories have many supporters. However, they suggest that habits linked to longevity, like quitting smoking and exercise, are useless. This is likely inaccurate, as research has continuously proven that these habits affect life expectancy.

Error theories, or damage theories, are the opposite of programmed theories. They hypothesize that aging is caused by cellular changes that are random and unplanned.

Error theories of aging include:

The genetic theory proposes that aging primarily depends on genetics. In other words, our life expectancy is regulated by the genes we got from our parents.

Since genes have predetermined traits, its thought this theory overlaps with programmed theories of aging.

Genetic theories include:

The limitation of genetic theories is that they disregard the importance of external factors. In fact, its estimated that just 25 percent of lifespan is influenced by genetics. This suggests that environmental and lifestyle factors play a major role.

Natural selection refers to the adaptive traits of an organism. These traits can help the organism adjust to their environment, so theyre more likely to survive.

According to evolutionary theories, aging is based on natural selection. It posits that an organism begins aging after they have reached their peak of reproduction and have passed down adaptive traits.

Evolutionary theories include:

These theories are still being researched and require more evidence.

Another theory is that biochemical reactions cause aging. These reactions occur naturally and continuously throughout life.

This theory is rooted in various concepts, including:

In recent decades, life expectancy around the world has increased. This is due many factors, including:

These factors can protect our cells and reduce cellular damage, thus increasing life expectancy.

In most parts of the world, women live longer than men. This is due to several biological, social, and environmental factors.

Women, on average, have more estrogen than men. Estrogen is the female sex hormone. Its been found to have anti-inflammatory and immune-boosting effects, which may protect women from certain diseases.

In contrast, the male sex hormone testosterone may suppress the immune system. Men typically have more of this hormone.

There are also behavioral differences between men and women. Generally, compared to men, women:

Though aging is inevitable, its possible to slow down some of the effects. You can do this by following healthy lifestyle habits.

Heres how to slow aging:

Aging is likely caused by a combination of reasons. Some theories suggest cells have a predetermined lifespan, while others claim its caused by error and damage. Other theories posit that aging is due to genetic, evolution, or biochemical reactions.

Aging is normal, but following a healthy lifestyle can help you live longer. Habits like eating well, exercising regularly, and wearing sunscreen can reduce your risk of disease and improve your quality of life.

See the original post here:
Why Do We Age, and Can Anything Be Done to Stop or Slow it? - Healthline

Posted in Gene Medicine | Comments Off on Why Do We Age, and Can Anything Be Done to Stop or Slow it? – Healthline

Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -…

Posted: at 6:26 pm

The single-center, prospective, observational study evaluated molecular response in patients with mNSCLC (n=51) receiving pembrolizumab-based therapy, as monotherapy or with chemotherapy, as first- or second-line treatment. Changes in ctDNA were evaluated from baseline to nine weeks post-therapy initiation, and correlated with clinical and radiographic response.

In the study, the Guardant360 test showed that molecular responders achieved improved durable clinic benefit (log mean 49.4% vs. 3.5%) and significantly longer progression-free survival (median 14.1 vs. 4.4 months) and overall survival (median 22.1 vs. 12.0 months) compared to non-molecular responders. Molecular response was also associated with radiologic response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) .

Unfortunately, only a subset of patients with metastatic non-small cell lung cancer will respond to pembrolizumab-based therapy, and their failure to achieve clinical benefit becomes evident after their disease has progressed, said Helmy Eltoukhy, Guardant Health CEO. This study adds to the growing body of evidence showing that our Guardant360 test can effectively measure molecular response, giving clinicians an earlier indication whether to continue or stop treatment, explore other therapeutic regimens, or enroll the patient in a clinical trial.

The Guardant360 test is used to guide treatment in metastatic non-small cell lung cancer as the number of treatment-relevant genomic alterations continues to grow. Using next-generation sequencing, Guardant360 analyzes 83 genes using cell-free tumor DNA from blood samples. The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors, including patients with metastatic non-small cell lung cancer. Last year, the FDA approved the Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).

"These are exciting results that further support the value of liquid biopsies as a noninvasive tool to measure early treatment responses by evaluating molecular response or changes in circulating tumor DNA," said Charu Aggarwal, MD, MPH, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penns Perelman School of Medicine and Abramson Cancer Center "We look forward to additional studies to help make this approach a reality in the clinical setting to personalize immunotherapy based treatment decisions for patients with metastatic non-small cell lung cancer."

The publication, titled Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy, can be found here: doi.org/10.1200/PO.20.00321.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential scope, impact or benefit of Guardant Health liquid biopsies which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Healths financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 as well as in its other reports filed with the Securities and Exchange Commission, including, when filed, its Quarterly Report on Form 10-Q for the period ended March 31, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Healths views as of any date subsequent to the date of this press release.

REFERENCES

1. Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.

2. Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.

3. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018: 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.

4. Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.

5. Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.

6. Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.

7. Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.

8. Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.

9. Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.

10. Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.00321.

Source: Guardant Health, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005031/en/

Read more from the original source:
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -...

Posted in Gene Medicine | Comments Off on Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -…

Hitting the hiking trail to escape pandemic-induced ennui? A bit of preparation could save your bacon | Courier-Herald – Enumclaw Courier-Herald

Posted: at 6:24 pm

Between better weather and a population still spiritually exhausted by COVID-19, outdoor experts are hoping to keep this summers impending rush of novice hikers and trekkers out of trouble.

Mount Rainier National Park information officer Kevin Bacher foresees a gangbuster season for backcountry enthusiasts this year, just like last summer. In 2020, park staff had to adapt to a huge number of people who were using trails and outdoor spaces with little prior experience, he said, and the park saw several record-setting weekends for attendance.

I think that was the real revelation about last summer, Bacher said. Not only were a lot of people coming out, but a lot of people who usually dont recreate (were) doing so for the first time.

On one hand, Bacher was thrilled to see people discover the wonders of the wilderness for the first time, developing skills, hobbies and connections to the outdoor world that they didnt have before.

But more adventure means more misadventure: The Seattle Times reported in early March that Mount Rainier National Park rangers embarked on 60 search-and-rescue operations in 2020, the most in the past five years, according to park data.

With visitor centers closed due to the pandemic, the park had to beef up ranger and volunteer presence on the trails in order to reach hikers that were often stepping foot for the first time on the mountain, unaware of safety or etiquette on the trail, Bacher said.

Hes hoping adventurers this summer are just as eager, and a little wiser.

KNOW YOUR TRAIL

Park rangers stress the value of researching the place youre visiting before heading out. Geographical and seasonal hazards are usually detailed online or in trail guides.

Its also helpful to learn CPR and the fundamentals of first aid and wilderness survival before embarking.

Before you leave, check the weather and road conditions in the area youre visiting, Bacher said. Wheres the closest gas station? Which roads are closed in the season youre visiting? Those arent mysteries you want to be solving on-the-day.

Mount Rainier, for instance, is open, but park visitor centers, the Paradise Inn and the Henry M. Jackson Visitor Center are closed due to the pandemic. Most park roads are closed, and all drivers are required to carry and be ready to use tire chains in the park in the winter season (November through the end of April).

Another step rangers and search-and-rescue volunteers stress: Make an itinerary for the day and share it with someone else who isnt going hiking. That way, if you dont return on time, that person can alert searchers as to where you were heading and when you were supposed to be back.

When you do head out, get an early start so as to maximize your time before nightfall (and your chances of getting a parking space). Travel with a group, especially in rough weather, so you and your friends can get help if someone is injured.

SUIT UP

You dont need a giant backpack full of gear, but packing clothes for a variety of temperatures, as well as rain, snow and sun is a good start, King County Search and Rescue volunteer Nathan Lorance said.

You might have a really warm cotton sweatshirt, but as soon as it gets wet, its like a t-shirt, Lorance said. Theres nothing there.

First-aid kits and tools to communicate and navigate are also crucial for when mishaps strike. The most common rescue calls searchers took were for minor injuries, Lorance said, like twisted ankles from slips and falls on hiking trails.

Accidents truly happen to everyone, Lorance said. You can have all the protective gear, all the training, and still trip on a rock.

Park officials stress these items for any kind of outdoor excursion:

Navigation: A compass, map of the area (a paper map doesnt run out of batteries) and a GPS.

Light: A flashlight or lamp with extra batteries (save your phone juice for communication).

Food: Extra food and water, and a way to filter water on longer journeys .

Severe weather protection: Raingear, insulating clothes and gloves.

Sun Protection: Sunscreen, sunglasses, chapstick and a hat.

Tools: A pocketknife and any other tools you foresee yourself needing.

Firestarters: Weatherproof matches and a lighter or other firestarters.

Communication: A fully-charged cell phone along with a backup battery.

First Aid Kit

Shelter: An emergency blanket for shelter on short trips, or a tent or tarp for longer trips .

If you plan to go on the water, a lifejacket or other flotation device is handy, too.

In an emergency, all these tools help you manage the one resource you cant buy: Time.

One of the things a lot of folks dont realize, is that unlike the fire department, our volunteers are coming from all over the county, Lorance said. As long as it takes you to hike in, its going to take us that long too. Having the basic essentials means you can be as comfortable as possible while waiting for additional help to survive.

WHERE AND WHEN TO START?

Spring is a great time to develop your physical and mental outdoor skills, especially if you plan to hike some of the grueling and high-elevation trails that wont be snow free until late summer.

Even in the summer, trails in the upper parts of Mount Rainier and other parks are subject to harshly cold weather and treacherous conditions. The trail that looks fantastic on Instagram might be buried in snow even when you visit it in June, Bacher said.

But maybe this is the time of year to hike places where the trails dont have the spectacular views of the mountain, but are really really beautiful, (with) forest trails through ancient trees, waterfalls that are really flowing beautifully because the snow is melting and feeding them, Bacher said.

Trail of the Shadows and Greenwater (AKA Meeker) Lakes are two such places in and around the Mt. Rainier National Park. The former provides a great beginners hike in the foothills of the mountain, while Greenwater Lakes serves up a smorgasbord of old growth forest, waterfalls, lakes and bridges. (Its even pet friendly.)

For picturesque views of the Carbon River Rainforest, consider the Rainforest Nature Loop Trail in the Carbon River area. Its a short, 0.3 mile loop that is snow-free year round.

And for those who like to see history up close, the Melmont Ghost Town can be traversed from Wilkeson/Carbonado via SR 165. No pass is needed to visit the ruins, which are slowly being reclaimed by nature.

Talk to us

Please share your story tips by emailing editor@courierherald.com.

To share your opinion for publication, submit a letter through our website https://www.courierherald.com/submit-letter/. Include your name, address and daytime phone number. (Well only publish your name and hometown.) Please keep letters to 500 words or less.

Excerpt from:

Hitting the hiking trail to escape pandemic-induced ennui? A bit of preparation could save your bacon | Courier-Herald - Enumclaw Courier-Herald

Posted in Space Travel | Comments Off on Hitting the hiking trail to escape pandemic-induced ennui? A bit of preparation could save your bacon | Courier-Herald – Enumclaw Courier-Herald

Elon Musk says his Starship rocket will land on Mars well before 2030 to create Base Alpha… – The Sun

Posted: at 6:24 pm

ELON Musk is set on getting to Mars as quickly as possible.

The billionaire claimed in a recent tweet that his company SpaceX would reach the Red Planet "well before 2030".

6

6

It comes as the latest prototype of the US firm's huge Starship rocket prepares for lift-off from a SpaceX facility in Texas.

"SpaceX will be landing Starships on Mars well before 2030," Musk tweeted on Tuesday.

"The really hard threshold is making Mars Base Alpha self-sustaining."

Musk has previously claimed that Starship a bullet-shaped stainless steel tower standing 160ft tall could reach Mars as early as 2022.

That would take the form of an unmanned flight carrying cargo to the planet.

Starship's first flight to Earth orbit will take place this year, according to SpaceX.

SN11, the company's latest prototype, fired up its engines as part of a series of static tests early this morning ahead of its first flight.

The rocket could blast into the sky this week, weather permitted. SpaceX will use the test to collect data that will inform future flights.

6

6

Expectations for the first flight of SN11 are high after its predecessor, SN10, met a fiery end earlier this month.

The prototype shot six miles into the air during a test flight on March 4 before touching down safely at the Starship facility in Boca Chica, Texas.

It stood upright on the ground for about 10 minutes before suddenly bursting into flames due to apossible methane leak.

Two other rockets, SN8 and SN9, met similar violent ends following flights in December and January.

6

Starship is in the early stages of development, and trial launches have thus far taken the form of high-altitude flights of a few miles.

SpaceX plans to reach orbit with the rocket in an unmanned flight by 2022.

Billionaire Musk, who is also CEO of Tesla, hopes to send a million people to Mars in his lifetime using a 1,000-strong fleet of the powerful rockets.

The finished product will stand 165ft (50 metres) tall and boast six of SpaceX's powerful Raptor engines.

What is SpaceX?

Here's what you need to know...

SpaceX is a cash-flushed rocket company that wants to take man to Mars.

It was set up by eccentric billionaire Elon Musk in 2002 and is based in Hawthorne, California.

SpaceX's first aim was to build rockets that can autonomously land back on Earth for refurbishment and re-use.

The technology makes launching and operating space flights more efficient, and therefore cheaper.

SpaceX currently uses its reusable Falcon 9 and Falcon Heavy rockets to fly cargo to the International Space Station (ISS) for Nasa.

It also carries satellites and other space tech into orbit for various government agencies and multinational companies.

The company took astronauts to the ISS for the first time in 2020.

Other future missions involve carrying tourists to the ISS and astronauts to the Moon and Mars.

Musk has repeatedly said he believes humanity must colonise Mars to save itself from extinction.

He plans to get a SpaceX rocket to the Red Planet by 2027.

According to SpaceX, the contraption will hit speeds of 15,000mph (25,000kph), making it the world's most powerful spacecraft.

In a series of tweets last year, Musk outlined how his Starlink plans would open up space travel to anyone, regardless of their income.

"Needs to be such that anyone can go if they want, with loans available for those who don't have money," he wrote.

Musk's plan involves building an expansive fleet of Starship vehicles, which comprise a huge rocket topped by a bullet-shaped spacecraft.

6

SpaceX says reusable rockets that can land and take off again make space travel more cost effective, accessible and sustainable.

However, the team has a long way to go before they can conduct Starship's first manned flight.

Musk is targeting a Mars cargo mission by 2022 and a manned flight to the Red Planet by 2024.

MOON MADNESSFull Worm Moon THIS week will be huge in the sky here's how to see it

VANISHING ACTMap of LOST continent that vanished 23million years ago finally revealed

HOLEY HELLStunning image of black hole reveals mysterious jets 'blowing matter'

STAR ATTRACTIONStar just exploded in the sky and YOU can see the supernova tonight

EAR WE GO!This test reveals your true hearing age and it only takes a few seconds

LUNAR LOVERSSupermoon 2021 dates when and how to spot all FOUR this year

In other news, the worlds firstreality show filmed in spacewill follow a contestant on a 10-day trip to the ISS in 2023.

Acids may have destroyed any evidence ofancient life on Mars, according to a new study.

And, a Nasa has unveileda new lunar landerthat could put astronauts back on the Moon in 2024.

Would you like to go to space? Let us know in the comments...

We pay for your stories! Do you have a story for The Sun Online Tech & Science team? Email us at tech@the-sun.co.uk

Continue reading here:

Elon Musk says his Starship rocket will land on Mars well before 2030 to create Base Alpha... - The Sun

Posted in Space Travel | Comments Off on Elon Musk says his Starship rocket will land on Mars well before 2030 to create Base Alpha… – The Sun

Redwire, An Innovative Space Infrastructure Company Serving The Fast-Growing Space Industry, To Become Publicly Traded Through Merger With Genesis…

Posted: at 6:24 pm

JACKSONVILLE, Fla.andHOUSTON, March 25, 2021 /PRNewswire/ --Redwire (or "the Company"), a leader in mission-critical space solutions and high reliability components for the next generation space economy, and Genesis Park Acquisition Corp. (NYSE: GNPK) ("Genesis Park"),a publicly tradedspecial purpose acquisition company, announced today that they have entered into a definitive merger agreement that will result in Redwire becoming a publicly traded company. The transaction is expected to be completed by the end of the second quarter of 2021, and at that time, Genesis Park Acquisition Corp. will change its name to Redwire and the company will trade on the NYSE.

Redwire provides critical space infrastructure technology and services and is uniquely positioned to deliver critical solutions to meet the growing needs of national security, civil, and commercialcustomers for a full spectrum of activity in space. The Company is differentiated from its peers because it offers both rich flight heritage, with more than 50 years of space flight experience and more than 150 missions flown, and unmatched innovations in space infrastructure, including over 100 patents and applications. Its infrastructure and services enable nearly every space mission, and Redwire sees increasing opportunities as decreasing launch costs continue to enable exponential growth in deployed space infrastructure.

Redwire is the leading developer of on-orbit servicing, assembly and manufacturing ("OSAM") capabilities, a transformational technology deploying 3D printing that enables customers to build satellites and other spacecraft in space, solving the size and other limitations posed by launch dynamics. Through the launch of raw materials into orbit, in-space manufacturing of component parts through 3D printing and other methods, and robotic assembly of highly functional objects, Redwire's OSAM technology enables lower cost deployment and higher power capabilities. The advantages of Redwire's in-space manufacturing will allow its customers to efficiently create more advanced products in space with greater performance characteristics than terrestrial based manufacturing methods, driving increased investment in space infrastructure from adjacent markets and the commercialization of space.

"Space-based capabilities and services are improving lives on Earth every day, and Redwire is an invaluable mission partner, providing technology that has been at the forefront of space infrastructure from the beginning. Today, the influx of private capital, new public sector space initiatives and decreased launch costs are driving tremendous growth in the space industry, which is projected to exceed $2 trillion by 2040," said Peter Cannito, Chairman and CEO of Redwire. "With our extensive space flight heritage and deeply innovative capabilities, we are accelerating humanity's expansion into space by delivering reliable, economical and sustainable infrastructure for future generations. As we enter this second golden age of space, Redwire is supplying the picks and shovels that enable nearly every space mission, supporting initiatives to help us better understand our planet, transform our space security infrastructure, and move humanity deeper into our solar system. We are thrilled to enter into this business combination with Genesis Park. With their extensive aerospace, operational and financial expertise and strong industry relationships, we are confident that Genesis Park is the right partner to propel Redwire's growth in the public market."

"We intended to find a profitable partner with strong management, powerful intellectual property and impressive organic growth. Redwire achieves that vision by transforming the future of space infrastructure and services at a time when the space industry is on the brink of exponential growth. Redwire is a proven, solidly profitable player in the space community and the undisputed leader in on-orbit 3D printing, servicing, assembly, and manufacturing. We also believe there is significant opportunity to accelerate growth through strategic combinations in the fragmented space landscape. Redwire has established itself as a first-mover consolidator and an acquirer of choice, and we believe its position will be further improved as a public company," said Paul Hobby, CEO and Director of Genesis Park. "We are very excited about Redwire's growth potential and we look forward to partnering with Peter and his team as they help usher in this new era of space exploration."

"As an innovative space infrastructure leader, Redwire is set to power a new age of space travel, exploration and commerce," said Kirk Konert, Partner at AE Industrial Partners. "With this transaction, Redwire will have even greater opportunities to drive growth and value by delivering tailored, responsive solutions for its growing customer base across the public and private sectors."

Redwire Highlights

Key Transaction TermsThe transaction values Redwire at a $615 million pro forma enterprise value, representing 9.6x estimated 2023 Adjusted EBITDA of approximately $64 million and 2.5x estimated 2025 Adjusted EBITDA of approximately $250 million. Assuming no redemptions by Genesis Park stockholders, the Proposed Transaction is expected to deliver approximately $170 million cash to the Redwire balance sheet. The proposed transaction is further supported by a $100 million fully committed and oversubscribed PIPE of common stock, priced at $10.00 per share, with participation by Senvest Management, LLC and Crescent Park Management, L.P.

Redwire's existing stockholders will hold approximately 55% of the fully diluted shares of common stock immediately following the closing of the business combination, assuming no redemptions by Genesis Park's existing public stockholders. AE Industrial Partners will remain a significant shareholder in Redwire following the completion of the proposed merger.

The transaction, which has been unanimously approved by the Boards of Directors of Redwire and Genesis Park, is subject to approval by Genesis Park's shareholders and other customary closing conditions.

Following the closing of the transaction, Redwire will continue to be led by Chairman and CEO Peter Cannito. The Redwire Board will be comprised of current Redwire Board members Pete Cannito, Dr. Reggie Brothers, Joanne Isham and Kirk Konert, along with Jonathan Baliff President, CFO & Director of Genesis Park; John Bolton, Advisor to Genesis Park and Les Daniels, Operating Partner of AE Industrial Partners.

Additional information about the proposed transaction, including a copy of the merger agreement and investor presentation, will be available in a Current Report on Form 8-K to be filed by Genesis Park with the Securities and Exchange Commission and at http://www.sec.gov. The investor presentation can also be found on https://www.genesis-park.com/redwire.

Investor Conference Call InformationRedwire and Genesis Park will host a joint investor conference call to discuss the proposed transaction on March 25, 2021 at 7:30 AM ET. To access the conference call, please visit https://www.genesis-park.com/redwire. The live call may also be accessed by dialing 1 877 876-9173 or 1 785 424-1667 providing the Conference ID 3086566. A replay of the call will be available on the Genesis Park website.

AdvisorsJefferies is serving as financial advisor and Kirkland and Ellis LLP is serving as legal counsel to Redwire. Greenhill and KPMG are serving as financial advisors, Jefferies is serving as sole placement agent for the PIPE and capital markets advisor, and Willkie Farr & Gallagher LLP and Sheppard, Mullin, Richter & Hampton LLP are serving as legal counsel to Genesis Park.

About RedwireRedwire is a new leader in mission critical space solutions and high reliability components for the next generation space economy. With decades of flight heritage combined with the agile and innovative culture of a commercial space platform, Redwire is uniquely positioned to assist its customers in solving the complex challenges of future space missions. For more information, please visitwww.redwirespace.com.

About Genesis Park Acquisition Corp.Genesis Park Acquisition Corp. ("GNPK") is a publicly traded special purpose acquisition company sponsored by an affiliate of Genesis Park, trading on the NYSE under the ticker symbol NYSE: GNPK.U. GNPK is one of the first aerospace and aviation services special purpose acquisition companies, and may pursue an initial business combination in any industry or geographic region, but specifically seeks to capitalize on the operational and investment experience of the GNPK management team and Board of Directors by focusing on companies that have significant growth prospects in the aerospace and aviation services sectors.

About AE Industrial Partners AE Industrial Partners is a private equity firm specializing in Aerospace, Defense, Space & Government Services, Power Generation, and Specialty Industrial markets. AE Industrial Partners invests in market-leading companies that can benefit from its deep industry knowledge, operating experience, and relationships throughout its target markets. AE Industrial Partners is a signatory to the United Nations Principles for Responsible Investing. Learn more atwww.aeroequity.com.

Redwire ContactsMedia: Austin Jordan321-536-8632Austin.jordan@redwirespace.com OR Investors: investorrelations@redwirespace.com

ReevemarkPaul Caminiti/Delia Cannan/Pam Greene212-433-4600redwire@reevemark.com

Forward Looking StatementsThis document includes "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information, including without limitation, forecasted revenue and revenue CAGR. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Genesis Park Acquisition Corp., Redwire or the combined company after completion of the Business Combination are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement governing the proposed business combination; (2) the inability to complete the transactions contemplated by the merger agreement due to the failure to obtain approval of the shareholders of Genesis Park Acquisition Corp. or other conditions to closing in the merger agreement; (3) the ability to meet NYSE's listing standards following the consummation of the transactions contemplated by the merger agreement; (4) the risk that the proposed transaction disrupts current plans and operations of Redwire as a result of the announcement and consummation of the transactions described herein; (5) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (6) costs related to the proposed business combination; (7) changes in applicable laws or regulations; (8) the possibility that Redwire may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties indicated from time to time in other documents filed or to be filed with the SEC by Genesis Park Acquisition Corp. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Genesis Park Acquisition Corp. and Redwire undertake no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Additional InformationIn connection with the proposed business combination between Redwire and Genesis Park Acquisition Corp., Genesis Park Acquisition Corp. intends to file with the SEC a preliminary proxy statement / prospectus and will mail a definitive proxy statement / prospectus and other relevant documentation to Genesis Park Acquisition Corp. shareholders. This document does not contain all the information that should be considered concerning the proposed business combination. It is not intended to form the basis of any investment decision or any other decision in respect to the proposed business combination. Genesis Park Acquisition Corp. shareholders and other interested persons are advised to read, when available, the preliminary proxy statement / prospectus and any amendments thereto, and the definitive proxy statement / prospectus in connection with Genesis Park Acquisition Corp.'s solicitation of proxies for the special meeting to be held to approve the transactions contemplated by the proposed business combination because these materials will contain important information about Redwire, Genesis Park Acquisition Corp. and the proposed business combination. The definitive proxy statement / prospectus will be mailed to Genesis Park Acquisition Corp. shareholders as of a record date to be established for voting on the proposed business combination when it becomes available. Shareholders will also be able to obtain a copy of the preliminary proxy statement / prospectus and the definitive proxy statement / prospectus once they are available, without charge, at the SEC's website at http://sec.gov or by directing a request to: investorrelations@redwirespace.com.

This document shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination.

Participants in the SolicitationGenesis Park Acquisition Corp. and its directors and officers may be deemed participants in the solicitation of proxies of Genesis Park Acquisition Corp. shareholders in connection with the proposed business combination. Genesis Park Acquisition Corp. shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Genesis Park Acquisition Corp. in Genesis Park Acquisition Corp.'s prospectus relating to its initial public offering filed with the SEC on November 24, 2020. Redwire and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Genesis Park Acquisition Corp. in connection with the Business Combination.

Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Genesis Park Acquisition Corp. shareholders in connection with the proposed business combination will be set forth in the proxy statement / prospectus for the transaction when available. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement / prospectus that Genesis Park Acquisition Corp. intends to file with the SEC.

View original content:http://www.prnewswire.com/news-releases/redwire-an-innovative-space-infrastructure-company-serving-the-fast-growing-space-industry-to-become-publicly-traded-through-merger-with-genesis-park-acquisition-corp-301255761.html

SOURCE Redwire; Genesis Park Acquisition Corp.

See the rest here:

Redwire, An Innovative Space Infrastructure Company Serving The Fast-Growing Space Industry, To Become Publicly Traded Through Merger With Genesis...

Posted in Space Travel | Comments Off on Redwire, An Innovative Space Infrastructure Company Serving The Fast-Growing Space Industry, To Become Publicly Traded Through Merger With Genesis…

How FF7’s Cid Is Different From Other Final Fantasy Characters Named Cid – Screen Rant

Posted: at 6:24 pm

Final Fantasy 7 featured the quintessential Cid, as Cid Highwind brought Dragoon skills to battles and had a story arc among the series' best.

With Final Fantasy VII RemakePart 2somewhere on the horizon, many RPG fans are excited to see how Cid Highwind could make his debut in a current-gen title. The presence of a character named Cid is a staple of theFinal Fantasyseries, but the Cid ofFinal Fantasy 7is unique, due to his presence as a main party member and his standout characterization - even among the other iconicFinal Fantasy 7 characters.

WhenFinal Fantasy 7was released for the PlayStation, Cid Highwind became the quintessential iteration of Cid. He remained a party memberuntil the end, making him a "main" character rather than a guest party member. Cid Highwind was a pilot and an engineer, reluctantly accepting the funding of the Shinra Corporation to pursue his dream of space travel. He was a chain-smoking, foul-mouthed cynic, not afraid to get his hands dirty by leaping into battle - literally - with a spear,much like prior Final Fantasy games' Dragoon character class.

Related:FF7 Remake Part 2 Plot Changes That Probably Won't Happen

Cids Tiny Bronco airplane served as one of the first modes of overworld travel in FF7; his Highwind airship allowed for full world travel in the latter parts of the story; and his rocket tookplayers into space during one key sequence. More important than his role as ferryman for the party, Cid Highwind fought alongside Cloud and the others up through the battle with Sephiroth and Jenova. He proved to be one of the game's strongest characters,andVenus Gospel, Cids ultimate spear, made him a wise choice for the final battles.

As powerful as Cid Highwind was as a damage dealer,his FF7 story was stronger. Cids childhood dream was to be the first human in space. He aborted the initial planned launch of his rocket due to Shera, his assistant, remaining in the blast zone to perform a last-minute safety check. Cid blamed Sheras overcautiousness for sabotaging his dream, and he wasunappreciative of and rudetowards her when the party first encountered them. In a later sequence, when the rocket was launched with the party onboard, an oxygen tank exploded, trapping Cid under debris. He recognized this as the same tank that Shera was inspecting at the time of the prior aborted launch, and that her prudence likely saved his life.

Though not given as much screen timeas FF7 protagonist Cloud, Cid's story was just as heartfelt, albeit more straightforward. Cid aspired towards one of humankinds loftiest goals - space travel - and saw Shera as the person who had sabotaged his dream. He then realizedhis ambition had blinded him, and his haste to travel among the stars caused him to lose sight of the details and blame Shera for his shortcomings. With the help of the party, Cid escaped the oxygen tank, humbled and forever changed by the experience.

AmongFinalFantasy's Cid characters,Cid Highwind is an all-time great. Prior iterations of Cid were airship pilots, engineers, and scientists fusing magic and technology. Subsequent games would take further liberties with Cid, casting him as a military academy instructor, a king cursed to be an Oglop, and even a villain, among other roles. Though the Thunder God Cid of theFinal Fantasy Tacticsspinoff could be considered a central character, Cid Highwind is the lone Cid to serve as a main party member in a numberedFinal Fantasygame. FF7's Cid is deeply human - flawed, ambitious, irritable, and dour, but also repentant and inspiring. As a memorable character with a great arc, there is good reason forfansto be excited to see the stubborn, rugged aeronauttake up his spear inFinal Fantasy VII Remake Part 2.

Next:Why We're Excited For Final Fantasy 7: Ever Crisis (And Why We're Worried)

Animal Crossing Player Creates Michigan Along With Tourism Brochure

Derek Garcia is a Game Feature Writer for ScreenRant. He lives with his wife, three dogs, and a likely excessive number of video game consoles. When he is not writing, playing video games, watching movies or television, or reading novels or comic books, he occasionally takes some time to sleep. Derek majored in journalism and worked for a print newspaper before discovering the internet. He is a fan of science fiction and fantasy, video game and tabletop RPGs, classic Hong Kong action movies, and graphic novels. After being immersed in nerd culture for many years, Derek is now happy to write about the media he enjoys instead of just ranting to his friends.

See original here:

How FF7's Cid Is Different From Other Final Fantasy Characters Named Cid - Screen Rant

Posted in Space Travel | Comments Off on How FF7’s Cid Is Different From Other Final Fantasy Characters Named Cid – Screen Rant

Auburn-area Proud Boy arraigned in federal court for Capitol riot charges – KUOW News and Information

Posted: at 6:23 pm

Ethan Nordean, 30, is accused of leading and participating in the January 6 riot on the U.S. Capitol in Washington DC.

Nordean, who lives near Auburn, is a self-described Sergeant of Arms for the far-right extremist group, Proud Boys.

During a hearing in the U.S. District Court for the District of Columbia via zoom Tuesday, prosecutors for the Department of Justice read aloud the multiple charges Nordean faces.

They include: conspiracy, obstruction of an official proceeding, obstruction of law enforcement during civil disorder, destruction of government property, entering and remaining in a restricted building or grounds, disorderly conduct in a restricted building or grounds, and aiding and abetting.

Nordean pleaded not guilty to all charges.

The Department of Justice says Nordean was a key figure in planning the riot and was close to the front of the crowd on January 6. Court documents say before the riot Nordean raised money online for body armor gear and radio communication equipment. Photos from that day allegedly show Nordean inside the Capitol Building.

Nordean could face more than 30 years in prison if convicted.

Three other defendants are involved in Nordeans case though only one appeared in court with him Tuesday. Joseph Biggs from Florida is seen in pictures with Nordean during the incident and is facing similar charges.

Nordean was a regular at far-right rallies around Seattle and Portland. Multiple videos on social media show Nordean fighting with other Proud Boys at political rallies. In summer 2020, he attended a Defend-SPD rally at Seattle City Hall.

Earlier this month a federal judge granted Nordeans request to be released from law enforcement custody pending his trial. He was ordered to spend most of his time at his home near Auburn and attended Tuesdays court hearing through zoom.

His next court date is set for April 1.

See the original post:

Auburn-area Proud Boy arraigned in federal court for Capitol riot charges - KUOW News and Information

Posted in Proud Boys | Comments Off on Auburn-area Proud Boy arraigned in federal court for Capitol riot charges – KUOW News and Information